Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed and objectively confirmed acute venous thromboembolism~* Active malignancy~* Life expectancy of at least 6 months~* Performance-Status according to Karnofsky Performance Scale ≥ 70 %~* Patient's compliance and geographical situation allowing an adequate follow up~* platelets ≥ 100.000 /μl, INR \< 1.5, PTT \< 40 sec.~* written informed consent of the patient prior to any procedure in connection with the study~* male and female patients with an age of at least 18 years~Exclusion Criteria:~* therapeutic anticoagulation \> 96 hours prior to study treatment~* known allergic reactions against the study drugs or the substances included therein~* known conditions associated with high risk of bleeding, known history of hemorrhagic diathesis~* acute clinically relevant bleeding in the last 2 weeks~* any history of spontaneous major/cerebral bleeding~* history of heparin induced thrombocytopenia II~* pregnant or breast-feeding women. Women of child-bearing potential must have a negative pregnancy test performed \< 7 days prior to start of the treatment~* severe renal insufficiency (GFR \< 30 ml/min)~* liver disease with coagulation impairment, including Child B and C~* cirrhosis~* acute medical illness~* treatment of the underlying cancer with experimental therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Arm A: Rivaroxaban
- low-molecular heparine (Type: ACTIVE_COMPARATOR): Arm B: standard treatment with low-molecular heparine

Based on this trial design, predict the completion outcome and termination type (if applicable).